Anixa Biosciences shares surge 11.50% intraday after assuming full IND sponsorship for breast cancer vaccine ahead of Phase 2 trials.

Anixa Biosciences surged 11.50% intraday following the announcement that it has assumed full sponsorship of the Investigational New Drug (IND) application for its breast cancer vaccine from the Cleveland Clinic, enabling the imminent start of a Phase 2 clinical trial. This move, coupled with positive Phase 1 trial results showing a 74% immune response rate in participants and the vaccine’s potential as a preventive and therapeutic treatment, positions the company to advance its development independently. The transition to sole sponsorship underscores operational control and prioritizes the program within Anixa’s pipeline, likely driving investor optimism amid prior stock volatility. The upcoming Phase 2 trial design and potential combination with Keytruda (pembrolizumab) further highlight near-term catalysts, aligning with the intraday price surge despite a broader seven-day decline.